Interview with Ulf Schneider, Managing Partner, RUSSIA CONSULTING
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
Address: 107031, Москва, Трубная площадь, дом 2, Бизнес-центр ‘Неглинная Плаза’,Russia
Tel: +7 (495) 229-29-99
Web: http://www.roche.ru/portal/roche.ru
Roche’ subsidiary in Russia was opened in 1991 and since then the company’s biotechnological medicines for the treatment of cancer, severe virus infections, autoimmune inflammatory diseases and metabolic disorders are widely marketed in Russia. The headquarters are located in Moscow, with subsidiaries in Saint-Petersburg and Novosibirsk. Roche’s development of novel and highly effective medicines is the result of numerous clinical trials conducted by the company according to GCP (Good Clinical Practice) worldwide, including Russia. Clinical trials in Russia are performed in the context of long-term cooperation with major Russian research centers. The leaders among them are Russian N.N. Blokhin Oncology Scientific Center in Moscow, Prof. N.N. Petrov Cancer Research Institute in Saint-Petersburg, Republican Oncology Center and AIDS Center in Kazan and many others. Roche closely monitors the quality of both local trials and parts of multinational clinical projects conducted in Russia.
A large number of Roche’s medicines are included into the Federal Reimbursement List due to the Federal program of reimbursement of certain categories of citizens. The company is a Good Corporate Citizen and takes an active part in social healthcare projects and initiatives. Roche supports the Equal Right to Life program initiated by oncologists. The goal of the program is to implement modern technologies of cancer diagnostics and treatment into regional healthcare institutions and to provide equal opportunities to proper treatment to all patients regardless of their social status or location.
Additional information on Roche in Russia can be found at www.roche.ru
The Roche company was founded in 1896 in Basel, Switzerland. At present Roche has subsidiaries in 150 countries worldwide and employs over 80,000 people. The investment in research and development in 2010 was over 9 billion Swiss francs , with Group sales of 47,5 billion Swiss francs. Roche wholly owns Genentech, USA and has a majority stake in Chugai Pharmaceutical, Japan.
Roche is one of the leading global pharmaceutical companies and the world’s leader in in vitro diagnostics and tissue-based cancer diagnostics. Personalised medicine strategy allows Roche to develop novel medicines and diagnostics tools that save and prolong patients’ lives significantly improving their quality of life.
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here